...
首页> 外文期刊>Cytokine >Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
【24h】

Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.

机译:用新型药物治疗多发性骨髓瘤的骨髓血管生成和血管生成因子。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: An increased bone marrow (BM) angiogenesis is associated with poor outcome in multiple myeloma (MM). OBJECTIVE: Angiogenesis study in MM treated with novel antimyeloma agents: thalidomide, lenalidomide, bortezomib, and with dexamethasone. PATIENTS AND METHODS: Forty-four patients with MM (14 newly diagnosed, 30 refractory/relapsed) were treated with novel agents at our institution. A BM biopsy was obtained before the initiation of therapy in 19. Angiogenesis was assessed by microvessel density (MVD) estimation in BM biopsies stained with the monoclonal anti-CD34 antibody, and by serum levels of angiogenic factors (VEGF, bFGF, and HGF) and cytokines (IL-6 and TNF-alpha). RESULTS: A positive correlation was found between BM plasma cell involvement and MVD estimation (p=0.01). However, MVD was not significantly correlated with either disease phase (p=0.065) or response to therapy (p=0.79). Neither baseline serum levels of angiogenic cytokines correlated to response to treatment. No significant correlation was found between BM MVD and serum levels of angiogenic cytokines. Serum levels of angiogenic cytokines before and after therapy showed a significant increase of bFGF (p=0.008). CONCLUSION: There is no relationship between MVD estimation and baseline serum levels of angiogenic cytokines, neither between each of them and response to therapy.
机译:简介:增加的骨髓(BM)血管生成与多发性骨髓瘤(MM)的不良预后相关。目的:在新型抗骨髓瘤药物沙利度胺,来那度胺,硼替佐米和地塞米松治疗的MM中进行血管生成研究。患者与方法:在本院接受新药治疗的MM患者44例(新诊断14例,难治性/复发30例)。在19开始治疗之前,已获得BM活检。通过单克隆抗CD34抗体染色的BM活检中的微血管密度(MVD)估计以及血管生成因子(VEGF,bFGF和HGF)的血清水平评估血管生成。和细胞因子(IL-6和TNF-α)。结果:发现BM浆细胞的参与与MVD估计值呈正相关(p = 0.01)。但是,MVD与疾病阶段(p = 0.065)或对治疗的反应(p = 0.79)均不显着相关。基线水平的血管生成细胞因子水平均与治疗反应无​​关。在BM MVD和血清中血管生成细胞因子水平之间没有发现显着相关性。治疗前后的血清血管生成细胞因子水平显示bFGF显着增加(p = 0.008)。结论:MVD估计值与基线血管生成细胞因子血清水平之间没有关系,两者之间以及对治疗的反应之间没有关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号